Opportunities
Active & Upcoming Solicitations
Closed Solicitations
| RPP # | Topic | Description | Submission Due Date |
|---|---|---|---|
| Coming Soon | New Vaccine Platforms (NVP) | The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration to identify technologies that (1) are safe; (2) are effective across multiple infectious disease threats from different pathogen families; and (3) enable efficient development and manufacturing. | TBD |
| RPP # (Date) | Requirement Topic | Closed Date |
|---|---|---|
| RFI: PBD1 (6/3/2026) | Request for Information: Protection Before Day One Vaccine: Advancing Broadly Protective Seasonal Influenza Vaccines with Pandemic Coverage | 7/29/2026 |
| RFI: BSL4 (7/9/2026) | Request for Information: Biosafety Level 4 Preclinical and Nonclinical Support for Medical Countermeasure Development | 7/24/2026 |
Request for Information: Repurposing Equipment for Drug Delivery | 7/23/2026 | |
| RFI: HiPe (6/16/2026) | Request for Information: High Performance Antigen Diagnostics | 7/17/2026 |
| Request for Information: Advanced Clinical Development and Licensure of an Adjuvanted Egg-based Influenza Vaccine | 7/10/2026 | |
| RPP-26-13-BundiVx (6/11/2026) | Bundibugyo virus Outbreak Response Vaccines (BundiVx) | 7/2/2026 |
| RFI Path(SM) (5/18/2026) | Request for Information: AI-Enabled Discovery of Broad-Spectrum Small-Molecule Inhibitors for Filoviruses | 6/17/2026 |
| RPP-26-12-ARDS (4/28/2026) | Host-Directed Therapeutics for the Prevention of Progression to ARDS | 5/26/2026 |
| RPP-26-10-RAPID (4/15/2026) | Rapid Antibody Production for Immunoassay Diagnostics (RAPID) | 5/18/2026 |
| RFI: NMJ MPS Plarforms for BoNT Potency Assay (4/20/2026) | Request for Information: Neuromuscular Junction (NMJ) Micro-Physiological Systems for Botulinum Neurotoxin (BoNT) Potency Measurement and Medical Countermeasures Evaluation | 5/11/2026 |
| Request for Information: PreventARDS (4/1/2026) | Host Directed Therapeutics for the Prevention of Progression to ARDS | 4/15/2026 |
| RPP-26-07-ASSURE (11/14/2025) | Assay Development for Superior Understanding of Response and Efficacy (ASSURE) | 2/24/2026 |
| New Vaccine Platforms Request for Information (11/26/2025) | New Vaccine Platforms | 1/30/2026 |
| Rapid Antibody Production for Immunoassay Diagnostics (RAPID) Request for Information (10/31/2025) | Rapid Antibody Production | 12/4/2025 |
| RPP-26-09-AgDx (10/23/2025) | Agnostic Diagnostics | 11/20/2025 |
RPP-25-06-DxR2 | Biothreat Diagnostic Rapid Response | 8/4/2025 |
| RPP-24-07-CentralIEIDLab (5/7/2025) | Central Influenza and Emerging Infectious Diseases Vaccine Immunoassay Laboratory Services | 5/30/2025 |
| RPP-24-08-mRNALongTerm (08/30/2024) | Rapid Pandemic Influenza and Emerging Infectious Disease Vaccine Development and Response Capability | 2/28/2025 |
| RPP-24-02-OralVx (09/09/2024) | NextGen Oral Formulation Vaccines for COVID-19 | 11/15/2024 |
| RPP-24-02-ODM (08/13/2024) | On-Demand Manufacturing | 9/25/2024 |
| RPP-24-03-SmMol (08/05/2024) | COVID-19 Small Molecule Therapeutics for PrEP | 9/20/2024 |
| RPP-24-06-DxR2 (3/27/2024) | Biothreat Diagnostic Rapid Response | 5/17/2024 |
| RPP-24-03-Treatment (02/21/2024) | Project NextGen: Therapeutics | 5/13/2024 |
| RPP-24-05-NGClinMfg (01/16/2024) | Project NextGen: Innovation in Clinical Manufacturing of COVID-19 Vaccines | 4/19/2024 |
| RPP-24-04-NGVxStats (2/23/2024) | NextGen Vaccines: Statistical Support, Correlates of Protection, and Meta-analysis | 3/27/2024 |
| RPP-24-04-NGVxAssays (2/15/2024) | NextGen Vaccines: Immune Assays | 3/22/2024 |
| RPP-24-02-Retail (2/2/2024) | Enabling Technology – Decentralized Clinical Trial – Retail/Pharmacy Focus | 3/20/2024 |
| RPP-24-03-PrEP (11/30/2023) | COVID-19 Monoclonal Antibody Therapeutics for PrEP | 1/19/2024 |
| RPP-24-02-HomeFocus (11/30/2023) | Enabling Technology – Decentralized Clinical Trial – Home Focus | 1/19/2024 |
| RPP-24-04-NGVx (11/30/2023) | NextGen Vaccinations: Phase 2B Clinical Trial Execution | 1/10/2024 |
RPP-24-01-mRNA | Accelerating Near-Term Availability of mRNA-based Pandemic Influenza Vaccine | 12/4/2023 |